Press Releases April 23, 2026 09:00 AM

STMicroelectronics to host investor call on the LEO opportunity

STMicroelectronics schedules investor webcast to discuss Low Earth Orbit (LEO) market opportunities.

By Leila Farooq
Share
Twitter Reddit Facebook LinkedIn
STM

STMicroelectronics announced an upcoming investor webcast to be held on May 4, 2026, focused on exploring business opportunities in the Low Earth Orbit (LEO) sector. The presentation will be led by the company's Microcontrollers, Digital ICs, and RF products group president, with a Q&A session following the webcast. The event highlights the company's focus on semiconductor technologies that support sustainable and cloud-connected autonomous applications.

STMicroelectronics to host investor call on the LEO opportunity
STM
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • STMicroelectronics to host an investor call detailing opportunities in the LEO satellite market.
  • The presentation is led by a key executive responsible for microcontrollers and RF products, indicating strategic focus areas.
  • The company emphasizes its commitment to sustainability and deployment of advanced semiconductor solutions.

STMicroelectronics to host investor call on the LEO opportunity

Geneva – April 23, 2026 – STMicroelectronics N.V. (NYSE: STM) will host a webcast for investors and analysts on May 4, 2026, on the LEO opportunity, hosted by Remi El-Ouazzane, President of ST’s Microcontrollers, Digital ICs and RF products Group.  

The presentation, starting at 3.30pm CET / 10.30am ET, will be followed by a Q&A session. A live webcast (listen-only mode) of the conference will be accessible at ST’s website, https://investors.st.com, and will be available for replay.

About STMicroelectronics
At ST, we are 48,000 creators and makers of semiconductor technologies mastering the semiconductor supply chain with state-of-the-art manufacturing facilities. An integrated device manufacturer, we work with more than 200,000 customers and thousands of partners to design and build products, solutions, and ecosystems that address their challenges and opportunities, and the need to support a more sustainable world. Our technologies enable smarter mobility, more efficient power and energy management, and the wide-scale deployment of cloud-connected autonomous things. We are on track to be carbon neutral in all direct and indirect emissions (scopes 1 and 2), product transportation, business travel, and employee commuting emissions (our scope 3 focus), and to achieve our 100% renewable electricity sourcing goal by the end of 2027. Further information can be found at www.st.com  

For more information, please contact: 

INVESTOR RELATIONS 
Jérôme Ramel 
EVP Corporate Development & Integrated External Communication 
Tel: +41.22.929.59.20 
jerome.ramel@st.com   

MEDIA RELATIONS 
Alexis Breton 
Group VP Corporate External Communications
Tel: +33.6.59.16.79.08
alexis.breton@st.com

Attachment

  • C3391C - Investor briefing on the LEO opportunity

Risks

  • Uncertainty on how the LEO market opportunity will translate into immediate revenue growth for STMicroelectronics.
  • Potential technological and competitive challenges in the fast-evolving satellite and semiconductor sectors.
  • Market reception is subject to broader semiconductor industry cyclicality and geopolitical factors impacting supply chains.

More from Press Releases

Agios Showcases RISE UP Phase 3 Results at EHA 2026 Plenary Session Reinforcing Strong Anti-Hemolytic Profile of Mitapivat in Sickle Cell Disease Jun 13, 2026 Rhythm Pharmaceuticals Presents Positive Interim Six-month Data from Phase 2 Trial of Setmelanotide in Patients with Prader-Willi Syndrome (PWS) at ENDO 2026 Jun 13, 2026 Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran (lonvo-z) in Patients with Hereditary Angioedema Jun 13, 2026 Arcadia Biosciences (RKDA) Announces Closing of $4 Million Private Placement Priced At-The-Market Under Nasdaq Rules Jun 12, 2026 Belite Bio Completes Rolling Submission of New Drug Application to U.S. Food and Drug Administration for Tinlarebant for the Treatment of Stargardt Disease Type 1 Jun 12, 2026